The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksHigh Impact•23 February 2026•

1 min read

Viking Therapeutics Gains as Novo Nordisk Hits 52-Week Low on Trial Failure

A man in a suit over a stock chart with 'Mondelez International' text, surrounded by chocolate, cocoa beans, factories, and shops.

Key Facts

1Novo Nordisk's stock hit a 52-week low after its REDEFINE 4 trial failed to demonstrate non-inferiority.

2Novo Nordisk's trial failed to show non-inferiority in weight loss compared to Eli Lilly's tirzepatide.

Viking Therapeutics shares surged recently as the obesity drug market experienced significant volatility following major clinical trial updates. Novo Nordisk's stock plummeted to a 52-week low after its REDEFINE 4 trial failed to demonstrate non-inferiority against Eli Lilly's tirzepatide. The trial results indicated that Novo Nordisk's weight loss treatment was less effective than Eli Lilly’s Zepbound and Mounjaro, disappointing investors and analysts alike. This clinical setback for the Danish pharmaceutical giant has shifted market sentiment toward its primary rival, Eli Lilly, and emerging competitors. Viking Therapeutics benefited from the broader sector momentum as investors look for alternative high-growth opportunities in the GLP-1 space. The outcome underscores the intense competition within the multi-billion dollar obesity market, where clinical efficacy remains the primary driver of stock valuation.